{
  "docId": "019dd923-5efe-75c0-8dfe-c33214992e60",
  "docSlug": "e4e961afe28a39dc",
  "documentTitle": "2026 Investor Deck",
  "authorId": "JPMorgan-IR",
  "authorName": "Summit Therapeutics",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 8,
  "pageCount": 15,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "case_study",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a structured grid to compare four distinct clinical trial programs.",
  "elementsJson": [
    "headline_text",
    "icon_grid",
    "process_diagram"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/8",
  "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60",
  "deckJsonHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60.json",
  "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-8",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-7321-74b0-ac7d-5fb24c382fa3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.86
      },
      "kind": "disclaimer",
      "text": "References: 1. Wang C, et al. HARMONI-2... [abbreviations list]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94fe480f-9e05-46a5-8343-5fb5252e8375",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.34,
        "x": 0.33,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ece46766-c310-4b66-a333-60493f4e5507",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.08,
        "x": 0.88,
        "y": 0.02
      },
      "kind": "image",
      "text": "Bispecific antibody structure (Anti-VEGF / Anti-PD-1)",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a581b0af-8a1b-4d11-b99d-33f274545ca6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.84,
        "x": 0.08,
        "y": 0.3
      },
      "kind": "list",
      "text": "HARMONI-2, HARMONI-6, HARMONI-A, HARMONI",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1de4d31-e84f-4b0b-86d5-aded9419ef09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.36,
        "x": 0.08,
        "y": 0.19
      },
      "kind": "paragraph",
      "text": "1L NSCLC Ivonescimab vs. Anti-PD-1 +/- chemo",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b65c6ac-0773-4053-8d69-606da33d6962",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.36,
        "x": 0.56,
        "y": 0.19
      },
      "kind": "paragraph",
      "text": "2L+ EGFRm NSCLC Ivonescimab + Chemo vs. Placebo + Chemo",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8560fc5d-82fd-468d-8923-c4e4685b218e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.1
      },
      "kind": "title",
      "text": "Four Phase III Clinical Studies with Positive Results",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09bfe769-9d69-4310-b19a-c7046753895c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Ivonescimab",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82e628d0-ed03-4351-9fb8-9d646fcec706",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180",
      "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential",
      "position": 0,
      "objective": "Highlighting the importance of timely progress in biopharma development",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 11,
      "from": 4,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "8d8d3398-4ad3-42b9-8a45-5223f61f6fa3",
      "evidence": "Slides 4-11 focus on Ivonescimab's clinical achievements and potential",
      "position": 1,
      "objective": "Positioning Ivonescimab as a high-potential therapy",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}